Analysts Issue Forecasts for IceCure Medical FY2027 Earnings

IceCure Medical Ltd (NASDAQ:ICCM) – Investment analysts at Brookline Capital Management dropped their FY2027 EPS estimates for IceCure Medical in a research note issued to investors on Tuesday, November 26th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of $0.23 for the year, down from their previous estimate of $0.25. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.27) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.33 EPS.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a report on Wednesday. Alliance Global Partners raised shares of IceCure Medical to a “strong-buy” rating in a research note on Friday, November 1st.

IceCure Medical Stock Up 5.8 %

Shares of NASDAQ:ICCM opened at $0.83 on Thursday. The company has a market capitalization of $37.96 million, a PE ratio of -2.77 and a beta of 0.48. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.57. The firm has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.73.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC bought a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.